Cortexyme (CRTX) Competitors

Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Do analysts rate CRTX or OMCL?

Omnicell has a consensus target price of $45.33, indicating a potential upside of 48.63%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Cortexyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cortexyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Which has better valuation and earnings, CRTX or OMCL?

Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	-$89.94M	-$2.97	-0.57
Omnicell	$1.11B	1.28	$12.53M	$0.50	61.00

Does the media favor CRTX or OMCL?

In the previous week, Omnicell had 18 more articles in the media than Cortexyme. MarketBeat recorded 19 mentions for Omnicell and 1 mentions for Cortexyme. Omnicell's average media sentiment score of 0.60 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cortexyme	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	5 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in CRTX or OMCL?

63.2% of Cortexyme shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 27.9% of Cortexyme shares are held by insiders. Comparatively, 2.5% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, CRTX or OMCL?

Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Is CRTX or OMCL more profitable?

Omnicell has a net margin of 2.01% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Cortexyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-70.96%	-63.53%
Omnicell	2.01%	4.27%	2.44%

Summary

Omnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks.